Incyte Corp
NASDAQ:INCY

Watchlist Manager
Incyte Corp Logo
Incyte Corp
NASDAQ:INCY
Watchlist
Price: 101.85 USD 0.42% Market Closed
Market Cap: 20B USD

Operating Margin
Incyte Corp

26.1%
Current
13%
Average
-4.3%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
26.1%
=
Operating Profit
1.3B
/
Revenue
4.8B

Operating Margin Across Competitors

No Stocks Found

Incyte Corp
Glance View

Incyte Corporation stands as a significant player in the biopharmaceutical landscape, where its roots are firmly planted in the research and development of novel therapeutics. Founded in 1991, Incyte initially carved its path focusing on genomics before pivoting towards drug development. This transformation catalyzed its growth, anchored by its commitment to discovering innovative ways to tackle unmet medical needs in oncology and inflammation. The company’s forte lies in its robust pipeline of targeted therapies, leveraging small molecules and monoclonal antibodies to alter the course of diseases. Incyte's approach is driven by a deep understanding of the biological pathways that underpin human health, allowing it to develop medicines that offer new hope to patients suffering from debilitating conditions. Incyte's commercial success is largely attributed to its flagship product, Jakafi (ruxolitinib), a groundbreaking oral selective inhibitor of Janus Associated Kinases (JAK1 and JAK2). Approved for the treatment of specific types of myelofibrosis and polycythemia vera, Jakafi represents a crucial revenue stream for the corporation. Beyond Jakafi, Incyte has been fruitful in diversifying its portfolio, fostering collaborative partnerships, and strategically licensing its assets to expand market reach and share risks. This dual strategy of internal innovation and external collaboration not only fuels Incyte’s financial engine but also reinforces its position in a competitive marketplace, as it continuously seeks out new frontiers in medical science to address complex diseases worldwide.

INCY Intrinsic Value
101.43 USD
Fairly Valued
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
26.1%
=
Operating Profit
1.3B
/
Revenue
4.8B
What is the Operating Margin of Incyte Corp?

Based on Incyte Corp's most recent financial statements, the company has Operating Margin of 26.1%.

Back to Top